The FDA gave a thumbs-up to the company's newest CF drug, Alyftrek, on Dec. 20, 2024. It approved Vertex's non-opioid drug Journavx for treating acute pain on Jan. 30, 2025. I fully expect both of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback